利伐沙班在中国上市时间

(Alias: Xarelto) developed by Bayer in Germany, the world's first highly selective oral anticoagulant that directly inhibits Factor

In June 2009, rivaroxaban was officially launched in China under the trade name Xarelto and is used to prevent or reduce the formation of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery.

Rivaroxaban is contraindicated in the following groups:

1. Patients who are allergic to rivaroxaban or any excipients in the tablets.

2. Patients with clinically obvious active bleeding.

3. Lesions or conditions with a significant risk of major bleeding, such as current or recent gastrointestinal ulcers, malignant tumors with a high risk of bleeding, recent brain or spinal injury, recent brain, spine or eye surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intravertebral or intracerebral vascular malformations.

4. Except for the situation of switching to or from rivaroxaban from other treatments, or giving the dose of unfractionated heparin (UFH) required to maintain a central venous or arterial catheter, any concomitant treatment with other anticoagulants is prohibited, such as UFH, low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, apixaban, dabigatran, etc.).

5. Patients with liver disease associated with coagulation abnormalities and clinically relevant bleeding risks, including patients with cirrhosis reaching Child Pugh classes B and C.

6. It is forbidden for pregnant and lactating women.